

## **IN THE CLAIMS**

This listing of claims below will replace all prior versions, and listings, of claims in the application:

### **Listing of Claims:**

1. (currently amended): A method for identifying subjects suspected of having ~~detecting~~ cancer, said method comprising detecting a soluble GPC3 protein level in a test sample obtained from a subject suspected of having cancer selected from the group consisting of blood, serum and plasma, and determining whether said detected soluble GPC3 level in the test sample obtained from a subject suspected of having cancer is greater than a control level of GPC3 in normal non-cancerous blood, serum or plasma ~~corresponding to the test sample~~.
2. (previously presented): The method of claim 1, wherein the soluble GPC3 protein is a N-terminal peptide of GPC3.
3. (previously presented): The method of claim 2, wherein the N-terminal peptide of GPC3 is a peptide fragment consisting of the amino acid sequence from the 1st amino acid to the 358th amino acid of SEQ ID NO: 4.
4. (canceled).
5. (previously presented): The method of claim 1, wherein the cancer is hepatic cancer.
6. (previously presented): The method of claim 1, comprising using an anti-GPC3 antibody.
7. (original): The method of claim 6, comprising using an anti-GPC3 antibody immobilized on a carrier and an anti-GPC3 antibody labeled with a labeling substances.
8. (original): The method of claim 7, wherein the labeling substances are biotin.

9-15. (canceled)

16. (previously presented): The method of claim 3, wherein the cancer is hepatic cancer.

17. (currently amended): The method of claim 6 [[4]] , wherein the cancer is hepatic cancer.

18. (previously presented): The method of claim 3, comprising using an anti-GPC3 antibody.

19-20. (canceled)

21. (new): The method of claim 5, wherein hepatic cancer cells express GPC3.

22. (new): The method of claim 16, wherein hepatic cancer cells express GPC3.

23. (new): The method of claim 17, wherein hepatic cancer cells express GPC3.